$40.4 Million is the total value of RiverVest Venture Management LLC's 5 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RPHM | Reneo Pharmaceuticals, Inc. | $19,298,085 | +16.1% | 2,534,220 | 0.0% | 47.73% | +158.8% | |
| ALLK | Buy | Allakos, Inc. | $11,321,675 | -46.9% | 4,987,522 | +2.0% | 28.00% | +18.5% |
| SPRB | Spruce Bioscience, Inc. | $6,635,996 | +5.1% | 2,936,281 | 0.0% | 16.41% | +134.4% | |
| Xilio Therapeutics, Inc. | $3,041,447 | -19.5% | 1,441,444 | 0.0% | 7.52% | +79.6% | ||
| VAPO | Sell | Vapotherm, Inc. | $132,965 | -29.3% | 52,552 | -87.4% | 0.33% | +57.4% |
| MIRM | Exit | Mirum Pharmaceuticals, Inc. | $0 | – | -1,621,118 | -100.0% | -46.52% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-10-30
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Allakos, Inc. | 12 | Q3 2023 | 88.4% |
| Spruce Bioscience, Inc. | 12 | Q3 2023 | 16.4% |
| Vapotherm, Inc. | 12 | Q3 2023 | 6.0% |
| Mirum Pharmaceuticals, Inc. | 11 | Q2 2023 | 54.9% |
| Reneo Pharmaceuticals, Inc. Fund 4 | 10 | Q3 2023 | 47.7% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 16.5% |
| Otonomy, Inc. | 1 | Q4 2020 | 0.4% |
View RiverVest Venture Management LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-10-30 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-02 |
| 13F-HR | 2022-02-07 |
| 13F-HR | 2021-11-12 |
View RiverVest Venture Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.